**Core tip**: Diet, as well as intestinal microbiota, is a key regulator of intestinal permeability, the alteration of which is central in the derangement of the gut-liver axis. In patients with non-alcoholic fatty liver disease (NAFLD), intestinal permeability is increased, promoting translocation of bacteria-derived products into the portal circulation and increasing hepatic exposure to injurious substances that stimulate hepatic inflammation and fibrosis. In animal models, high-fat diet or high-fructose intake has been associated with increased gut permeability. The aim of this study was to detect diet-induced modification of intestinal permeability in non-diabetic patients with NAFLD undergoing a Mediterranean diet or a low-fat diet.

INTRODUCTION
============

In western countries, non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is closely associated with an unhealthy lifestyle. Patients with NAFLD are reported to engage in an excessive consumption of total energy, refined carbohydrates (including fructose), saturated fats and cholesterol with an insufficient intake of polyunsaturated fats, fibres and antioxidants (vitamin C and vitamin E)\[[@B1],[@B2]\]. Because there is no pharmacotherapy currently available for patients with NAFLD, lifestyle modifications remain the cornerstone management\[[@B3],[@B4]\]. In overweight/obese patients with NAFLD, calorie restriction drives weight loss, reducion of liver fat, and histological improvement of non-alcoholic steatohepatitis (NASH)\[[@B5],[@B6]\] , but there are conflicting data on which hypocaloric dietary plan should be adopted according to the macronutrient composition\[[@B7],[@B8]\].

Low-fat diets, popular in the treatment of obesity, are reported to be more effective than low-carbohydrate diets in reducing total cholesterol and low-density lipoprotein (LDL) cholesterol concentrations\[[@B9]\], whereas low-carbohydrate diets can be more effective than low-fat diets in increasing high-density lipoprotein (HDL) cholesterol concentrations and reducing triglyceride levels and transaminase levels through a greater reduction in the concentration of 24-h circulating insulin under both isocaloric and hypocaloric conditions\[[@B10]-[@B13]\].

The Mediterranean diet, first described in the 1960s by Ancel Keys, is a low-carbohydrate nutritional model inspired by the traditional diets of countries along the Mediterranean Sea Basin, an area of origin for the *Olea Europaea* plant\[[@B14],[@B15]\]. European guidelines for management of NAFLD suggest the Mediterranean diet as a reference for macronutrient composition\[[@B16]\].

Diet, as well as intestinal microbiota, is a key regulator of intestinal permeability, the alteration of which is central in the derangement of the gut-liver axis\[[@B17]\]. In patients with NAFLD, intestinal permeability is increased, promoting translocation of bacteria-derived products into the portal circulation and increasing hepatic exposure to injurious substances that stimulate hepatic inflammation and fibrosis\[[@B18]\]. In animal models, adaptation of a high-fat diet or high-fructose intake has been associated with increased gut permeability and metabolic endotoxiemia\[[@B19]-[@B21]\]. Although diet can significantly influence intestinal permeability, clinical studies investigating the effects of dietary interventions on the intestinal permeability of NAFLD patients are lacking.

The aim of this study was to detect diet-induced modification of intestinal permeability in non-diabetic patients with NAFLD undergoing a Mediterranean diet or a low-fat diet in a crossover comparison. Secondary outcomes were modifications in transaminase levels, body weight and waist circumference.

MATERIALS AND METHODS
=====================

Patients
--------

This single-centre prospective dietary intervention open-label trial was conducted in the outpatient clinic for Gastroenterology and Liver Disease at the Catholic University of the Sacred Heart of Rome and was approved by the local Ethics Committee. Every patient provided written informed consent before enrolment.

Adult patients with a histologically confirmed diagnosis of NAFLD and increased levels of alanine aminotransferase (ALT) \> 1.5 time the upper normal limit (30 IU/L in males and 19 IU/L in females) were included\[[@B22]\]. We chose to include only patients with elevated transaminase levels at baseline because one of the secondary end-points of the study was a reduction in transaminases. All other causes of liver damage were ruled out. In particular, all patients had negative serological markers for hepatitis B and hepatitis C, an alcoholic consumption of \< 30 g of ethanol for men and \< 20 g for women, were not taking any hepatotoxic drug, did not have evidence of metabolic disease (Wilson\'s disease, hereditary haemochromatosis) or autoimmune disease (autoimmune hepatitis, primitive biliary cirrhosis, primitive sclerosing cholangitis). The main exclusion criteria were the presence of liver cirrhosis, diabetes, body mass index (BMI) ≥ 35 kg/m² or previous bariatric surgery, because these conditions already have well-established dietary recommendations.

Participants had to have stable body weight (variation \< 5% within the preceding 3-mo period) and maintain their usual level of physical activity for the duration of the intervention. The participants who were already taking medications had to be on a stable regimen for at least 6 months before study enrolment. The dose of these medications had to remain stable during the study. Participants were allowed to start a new medication only if it was medically necessary. No consumption of supplements (including vitamin E) was allowed during the study.

Design of the study
-------------------

Patients underwent a dietary treatment via a crossover design lasting 48 wk: 16-wk of a Mediterranean diet (W1-W16), 16-wk of a free wash-out diet (W17-W32) and 16-wk of a low-fat diet (W33-W48).

Both the Mediterranean diet (40% carbohydrates, 40% fat with \< 10% saturated fat, 20% protein) and low-fat diet (62% carbohydrates, 18% fat, 20% protein) were caloric-equivalent (1400 Kcal) and were processed by the dietary service of our Hospital in accordance with international standards (Supplementary Tables 1-3). We chose hypocaloric diets as opposed to isocaloric diets because the beneficial effect of caloric restriction on NAFLD has been well-documented in the literature, and it would have been unethical to not have provided patients with an indication recommended by all guidelines.

Before starting each diet and at the end of each dietary period, patients underwent a medical examination, provided and performed electrocardiogram and blood tests, including blood count, ALT, aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), alkaline phosphatase, bilirubin, blood glucose, basal insulinaemia, total cholesterol, HDL cholesterol, triglycerides, albumin, creatinine, sodium, potassium, and urine test. All blood tests were determined by standard methods in a certiﬁed clinical chemistry laboratory.

Anthropometric measurements were directly measured by the same dietitian at every visit: weight (light clothing, shoes off) to the nearest 0.1 kg, height (standing tall, feet hip-width apart and head level) to the nearest 1 cm, waist and hip circumference (tape lying flat and level, taut but not tight) to the nearest 1 cm.

All patients were re-evaluated bimonthly by the same dietitian for compliance to the prescribed diet and physical activity level. Dietary history was carried out by means of a 24-h recall\[[@B23]\], food frequency questionnaire (including alcohol intake)\[[@B24]\], and 10-point Mediterranean-diet Score\[[@B25]\], with subsequent calculation of caloric-nutritional intake. Physical activity was assessed at both baseline and at the end of each dietary period using the International Physical Activity Questionnaire (IPAQ) long form\[[@B26]\].

Evaluation of intestinal permeability
-------------------------------------

Intestinal permeability was evaluated at baseline and at the end of each diet period using the validated method of urinary excretion of chromium-51 ethylene diamine tetraacetate excretion testing (51Cr-EDTA). Many methods for measuring intestinal permeability in the clinical setting have been validated (*e.g*., lactulose/mannitol, sucralose, sucrose), but none has proven to be superior to others nor has gained a place in everyday clinical practice\[[@B17]\]. In our study we chose to use the 51Cr-EDTA test because it is poorly influenced by bacterial degradation in cases of small intestine bacterial overgrowth, sometimes associated with NAFLD, and it is easily repeatable and less time-consuming for the health workers compared to oligosaccharides-based tests\[[@B27]\] .

After an overnight fast, patients drank 1.85 MBq 51CrEDTA (Amersham Health, England) in 10 mL water, and urine was collected for the next 24 h. Two 3-mL samples of the collected urine were assessed with a gamma counter (LKB-Wallac 1282 Compugamma, Turku, Finland), as previously described\[[@B28]\]. 51Cr-EDTA clearance was calculated using the following formula: \[(Mean urinary counts × Urinary volume) × (Standard counts × 50)\]^-1^. Results were expressed as percentages of the ingested dose. In normal subjects, 1%-3% of an orally administered dose of 51Cr-EDTA is absorbed by the gastrointestinal tract.

Statistical analysis
--------------------

The data were analysed using a descriptive statistical method (Statistical Package for Social Sciences 17.0), and the results were expressed as the means and standard deviations. Student's *t*-tests were used to determine statistically signiﬁcant differences (*P* \< 0.05) between groups.

RESULTS
=======

Fifty-four patients with NAFLD underwent liver biopsy at our centre during the two-year timeframe (Figure [1](#F1){ref-type="fig"}). Twenty-four patients were not eligible for the study because of one or more exclusion criteria (16 patients for ALT levels \< 1.5 time the upper normal limit, 5 patients for diabetes, 3 patients for BMI ≥ 35 kg/m²). Ten patients refused to participate in the study (5 patients because of lack of motivation to start a diet program and 5 patients because of working reasons). Twenty patients were enrolled and started the Mediterranean diet. Eighteen patients completed the 16-wk Mediterranean diet (W1-W16), whereas 2 patients dropped out due to poor compliance to the diet. After 16 weeks of a free wash-out diet (W17-W32), 4 patients refused to continue the study. 14 patients started the 16 wk of the low-fat diet (W33-48), but 2 patients dropped out due to poor compliance to the diet. Twelve patients completed the entire protocol. According to the results of IPAQ long form, no patient significantly changed his or her level of physical activity during the study.

![Flow chart of study patients.](WJG-25-509-g001){#F1}

Demographics
------------

Clinical and laboratory features of the cohort are summarized in Table [1](#T1){ref-type="table"}. Overall, 18 (90%) of the patients enrolled were male, with a mean age of 42.7 years. Thirteen (65%) patients had hypertension, 5 (25%) had hypercholesterolemia, and 13 (65%) met diagnostic criteria for metabolic syndrome according to ATP III\[[@B29]\] (Table [1](#T1){ref-type="table"}). Based on liver biopsy results, 12 (60%) presented with a Kleiner score of 3-4 and 8 (40%) with a Kleiner score ≥ 5, indicative of NASH\[[@B30]\]. Mean BMI was 30.9 ± 3.6, mean waist circumference was 107.2 ± 9.0 cm, mean hip circumference was 107.5 ± 6.7 cm, mean waist/hip ratio was 0.99 ± 0.05, mean systolic blood pressure was 129.0 ± 14.3 mmHg, and mean diastolic blood pressure was 84.5 ± 11.4 mmHg. Mean fasting blood glucose was 93.8±13.1 mg/dL, mean HOMA-IR score\[[@B31]\] was 5.2, mean total cholesterol was 186.5 ± 45.1 mg/dL, mean LDL cholesterol was 112.9 ± 44.1 mg/dL, mean HDL cholesterol was 41.7 ± 6.3 mg/dL, mean triglycerides were 139.0 ± 90.4 mg/dL, mean ALT levels were 80.5 ± 41.6 IU/L, mean AST levels were 39.8 ± 15.1 IU/L, and mean GGT levels were 102.3 ± 123.5 IU/L.

###### 

Effects on clinical, metabolic and intestinal permeability paramethers after 16 wk of Mediterranean diet or low-fat diet in patients with non-alcoholic fatty liver disease

                                    **Basal**       **After Mediterranean diet**   ***P* value (≥ 0.05 NS)**   **After wash-out**   **After low-fat diet**   ***P* value (≥ 0.05 NS)**
  --------------------------------- --------------- ------------------------------ --------------------------- -------------------- ------------------------ ---------------------------
  Weight (kg)                       91.3 ± 10.9     86.0 ± 12.4                    0.003                       86.3 ± 8.4           85.7 ± 9.4               NS
  Body mass index                   30.9 ± 3.6      29.3 ± 4.1                     NS                          29.7 ± 2.9           29.3 ± 3.2               NS
  Waist (cm)                        107.2 ± 9.0     99.3 ± 11.5                    0.001                       102.0 ± 11.5         96.8 ± 11.5              NS
  Hip (cm)                          107.5 ± 6.7     103.9 ±6.9                     0.001                       103.7 ± 6.3          101.7 ± 11.1             NS
  Waist/hip ratio                   0.99 ± 0.05     0.96 ± 0.08                    NS                          0.97 ± 0.04          0.95 ± 0.06              NS
  Systolic blood pressure (mmHg)    129.0 ± 14.3    130.5 ± 20.3                   NS                          130.0 ± 8.9          122.5 ± 17.5             NS
  Diastolic blood pressure (mmHg)   84.5 ± 11.4     81.0 ± 14.7                    NS                          79.2 ± 9.2           75.8 ± 14.3              NS
  Glycemia (mg/dL)                  93.8 ± 13.1     92.9 ± 11.8                    NS                          95.5 ± 9.0           96.2 ± 7.3               NS
  HOMA-IR                           5.2 ± 2.5       3.5 ± 2.1                      NS                          4.3 ± 1.2            3.8 ± 1.5                NS
  Total Cholesterol (mg/dL)         186.5 ± 45.1    176.9 ± 42.9                   NS                          186.3 ± 65.7         177.0 ± 50.5             NS
  LDL cholesterol (mg/dL)           112.9 ± 44.1    113.7 ± 35.2                   NS                          119.7 ± 55.8         109.5 ± 44.6             NS
  HDL cholesterol (mg/dL)           41.7 ± 6.3      42.1 ± 9.3                     NS                          44.7 ± 4.5           44.7 ± 4.7               NS
  Tryglicerid (mg/dL)               139.0 ± 90.4    105.4 ± 45.4                   NS                          110.5 ± 48.7         105.8 ± 36.1             NS
  ALT (UI/L)                        80.5 ± 41.6     52.2 ± 32.3                    0.0001                      56.2 ± 33.8          58.3 ± 38.7              NS
  AST (UI/L)                        39.8 ± 15,1     33.4 ± 15.7                    0.01                        26.5 ± 10.4          29.0 ± 11.3              NS
  GGT (UI/L)                        102.3 ± 123.5   89.6 ± 129.5                   NS                          100.7 ± 128.3        70.7 ± 75.3              NS
  Albumin (g/dL)                    4.6 ± 0.3       4.5 ± 0.3                      NS                          4.6 ± 0.4            4.5 ± 0.4                NS
  Emoglobin (g/dL)                  15.1 ± 1.1      14.9 ± 1.1                     NS                          15.4 ± 1.3           15.3 ± 1.3               NS
  Creatinin (mg/dL)                 0.9 ± 0.1       0.9 ± 0.1                      NS                          0.9 ± 0.1            0.9 ± 0.1                NS

W1: Week 1; W16: Week 16; W32: Week 32; W48: Week 48; HOMA-IR: Homeostatic model assessment - insulin resistance; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine transaminase; AST: Aspartate transaminase; GGT: Gamma glutamyl trasferase.

Nutritional assessment
----------------------

At the baseline nutritional assessment, patients ingested a mean of 1798 kcal per day, divided as follows: 53.2% carbohydrates, 18.3% proteins and 28.4% lipids, of which 11.4 g were saturated fat, 4.5 g polyunsaturated fats, 29.7 g monounsaturated fatty acids and 248.2 g cholesterol (Table [2](#T2){ref-type="table"}). Regarding micronutrients, patients ingested a mean of only 16.9 g of total daily fibre, 88.8 mcg of vitamin A, 68.3 g of vitamin C, 7.7 g of vitamin E and 9.5 g of total iron. Regarding the daily nutrient distribution, 22% of patients usually did not have breakfast; 45% were not used to having a full lunch and 75% did not have a mid-morning and afternoon snack. The results of the food frequency questionnaire administered at baseline are shown in the supplementary appendix. According to the 10-point Mediterranean-diet Score, 45% of patients obtained a score ≤ 3, indicative of a food pattern poorly adherent to the Mediterranean diet.

###### 

Nutritional assessment

                                    **Basal (W1)**   **After mediterranean diet (W16)**   **After wash-out (W32)**   **After low-fat diet (W48)**
  --------------------------------- ---------------- ------------------------------------ -------------------------- ------------------------------
  Macronutrients                                                                                                     
  kcal per day                      1798             1421                                 1853                       1414
  Carbohydrates (%)                 53.2             40.5                                 55.0                       62.1
  Proteins (%)                      18.3             21.1                                 16.5                       20.2
  Lipids (%)                        28.4             38.4                                 28.5                       17.7
  Saturated fat (g)                 11.4             7.2                                  9.0                        5.5
  Polyunsaturated fats (g)          4.5              3.5                                  4.2                        2.6
  Monounsaturated fatty acids (g)   29.7             27.2                                 25.0                       14.4
  Cholesterol (g)                   248.2            157.5                                258.2                      153.3
  Micronutrients                                                                                                     
  Total daily fiber (g)             16.9             28.2                                 16.8                       21.2
  Vitamin A (mcg)                   88.8             47.6                                 86.1                       33.4
  Vitamin C (g)                     68.3             143.3                                72.6                       119.3
  Vitamin E (g)                     7.7              7.8                                  6.7                        3.3
  Total iron (g)                    9.5              15.5                                 10.7                       12.7

W1: Week 1; W16: Week 16; W32: Week 32; W48: Week 48.

Effects of nutritional intervention
-----------------------------------

An assessment of adherence to the two diet periods is shown in Table [2](#T2){ref-type="table"}. A total of 18 patients out of 20 were judged to be adherent to the Mediterranean diet, and 12 out of 14 patients were judged to be adherent to the low-fat diet.

At the end of 16 wk of Mediterranean diet (W1-W16), were observed a significant reduction in mean body weight (-5.3 ± 4.1 kg, *P* = 0.003), mean waist circumference (-7.9 ± 4.9 cm, *P* = 0.001), mean hip circumference (-8.2 ± 8.6 cm, *P* = 0.001), and mean transaminase levels (ALT -28.3 ± 11.9 IU/L, *P* = 0.0001; AST -6.4 ± 56.3 IU/L, *P* = 0.01). (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

![Evolution of the parameters body weight, waist circumference and level of transaminases during the study. ALT: Alanine transaminase.](WJG-25-509-g002){#F2}

At the end of 16 wk of the free wash-out diet (W16-W32), no significant variations were observed in anthropometric or laboratory parameters compared to results observed at the end of the Mediterranean diet period. At the end of the 16 wk of the low-fat diet (W32-W48), no significant variations were observed in any of the anthropometric or laboratory parameters analysed (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

Analysing only patients who completed both diets (Figure [3](#F3){ref-type="fig"}), we observed that after 16-weeks of the Mediterranean diet, compared to 16-wk of the low-fat diet in the same patients, there was a significant reduction in mean body weight (-7.8 ± 2.3 kg *vs* 0.6 ± 2.4 kg, *P* = 0.004), mean waist circumference (-11.2 ± 2.6 cm *vs* 4.6 ± 7.6 cm, *P* = 0.04), and mean ALT levels (-28.5 ± 9.5 IU/L *vs* 2.2 ± 5.5 IU/L, *P* = 0.04).

![Comparison between variations obtained after 16 wk of mediterranean diet or low-fat diet. ALT: Alanine transaminase.](WJG-25-509-g003){#F3}

No adverse events related to either the Mediterranean diet or low-fat diet were recorded.

Intestinal permeability
-----------------------

Seventy percent of patients had intestinal permeability alteration at baseline with a mean percentage retention of 51Cr-EDTA of 5.4% ± 4.7% (Figure [4](#F4){ref-type="fig"}). No significant changes in intestinal permeability were observed at the end of the Mediterranean diet period (6.0% ± 3.3%), after the wash-out period (7.2% ± 5.4%) or at the end of the low-fat diet period (7.3% ± 4.3%).

![Intestinal permeability. 51Cr-EDTA: Chromium-51 ethylene diamine tetraacetate excretion testing.](WJG-25-509-g004){#F4}

DISCUSSION
==========

Our crossover study demonstrated a significant reduction in body weight, waist circumference and transaminase levels after 16 wk of Mediterranean diet and maintenance of these results following a low-fat diet period. The Mediterranean diet is a low-carbohydrate high-unsaturated fat nutritional model that appears to be an ideal diet for improving insulin sensitivity in NAFLD patients\[[@B32]\]. In a study conducted in Israel with 259 diabetic obese patients, a Mediterranean diet was superior to two types of low-fat diets for reducing serum transaminase levels at 6 and 12 mo\[[@B33]\]. A meta-analysis demonstrated that omega-3 fatty acids, found in the Mediterranean diet, were beneficial for reducing hepatic steatosis\[[@B34]\]. In a small pilot study conducted in Australia with 12 patients with NAFLD, 6 wk of *ad libitum* Mediterranean diet were more effective than a low-fat diet for improving insulin sensitivity and reducing the fat content in the liver, measured by magnetic resonance spectroscopy, even without a change in weight or serum transaminase levels\[[@B35]\]. A randomized trial of the Mediterranean diet *vs* a low-fat diet (MEDINA) is currently ongoing in Australia and New Zealand, with improvement of insulin sensitivity set as the primary end-point\[[@B36]\]. The Prevención con Dieta Mediterránea (PREDIMED) trial, conducted in Spain with over 7000 persons at high risk for cardiovascular disease, showed that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events over a control diet\[[@B37]\]. In a subsequent sub-analysis, it was observed that patients with lower adherence to the Mediterranean diet had higher values of serum transaminases\[[@B38]\]. In our study, we confirmed that 16 weeks of a Mediterranean diet was effective for improving serum transaminase levels in patients with NAFLD. Recently, a randomized 12-wk interventional study conducted in Australia with *ad libitum* isocaloric diets demonstrated that both a Mediterranean and a low-fat diet reduced hepatic steatosis and transaminases by a similar degree, but the Mediterranean diet also improved Framingham risk scores\[[@B39]\].

The choice of a crossover design for this study was based on our attempt to control confounding factors in the best possible way, as each subject served as their own control. However, it is very likely that there was an effect of the sequence of the diets, because the patients arrived at the end of a free wash-out diet (W32) with the same clinical characteristics that they had reached at the end of the Mediterranean diet (W16). In other words, despite a planned wash-out period, patients did not start the low-fat diet in the same condition in which they started the Mediterranean diet. We can therefore state that, in our study, 16 weeks of a low-fat diet was sufficient to maintain the benefits obtained after the Mediterranean diet period.

It is well-known that elevated concentrations of fructose favour pro-inflammatory microbiota, thereby producing endotoxins and suppressing production of short-chain fatty acids that are essential for intestinal barrier function\[[@B40]\]. Pro-inflammatory microbiota and their products recruit macrophages and bind to toll-like receptors, leading to the release of cytokines, such as tumour necrosis factor-α, causing mucosal inflammation\[[@B41]\]. Subsequently, inflammation decreases expression of tight junction proteins, resulting in higher permeability of the gut barrier\[[@B42]\]. Diet-induced increases in blood lipopolysaccharide levels are known as metabolic endotoxaemia and play an important role in the activation of Toll-like receptor-mediated low-grade liver inflammation, which are associated with NAFLD and NASH\[[@B43]\]. Current evidence from animal studies suggests that a high-fat diet or a high-fructose diet can induce metabolic endotoxaemia by altering the intestinal tight junction proteins, mainly zonula occludens-1 and occludin\[[@B44]-[@B47]\]. Our group has provided evidence that increased intestinal permeability in NAFLD patients is caused by disruption of intestinal tight junctions, as documented by decreased expression of zonula occludens 1 in the intestinal mucosa\[[@B48]\]. In NAFLD adolescents, postprandial endotoxin levels were increased compared to healthy subjects in response to fructose, but not glucose, beverages (consumed with meals) in a 24-hour feeding challenge\[[@B49]\]. On the other hand, there are currently no data concerning diet modulation of intestinal permeability in patients with NAFLD, and it is thought that a healthy diet can reduce intestinal permeability in patients with NAFLD by restoring the integrity of tight junctions. The Mediterranean diet contains a high intake of mono- and polyunsaturated fatty acids, fibres, polyphenols, antioxidants and phytochemicals; many of these components promote short-chain fatty acid-producing gut bacteria and have significant prebiotic effects\[[@B50]\]. As such, we hypothesized a therapeutic effect of the Mediterranean diet for reducing impaired intestinal permeability in patients with NAFLD. Under conditions of enhanced intestinal permeability, an increased fraction of orally administered 51Cr-EDTA crosses the intestinal epithelium along the paracellular pathway, enters the blood stream and is rapidly cleared through glomerular ﬁltration\[[@B27]\]. Arslan et al\[[@B51]\] found that 51Cr-EDTA excretion is a good indicator of the severity of gut-mucosal inﬂammation and loss of tight junctions. In our study, the majority of patients presented at baseline, as expected, with high intestinal permeability evaluated according to 51Cr-EDTA, but neither 16 wk of a Mediterranean diet nor 16 wk of a low-fat diet were sufficient to modulate it.

In our view, the modulation of intestinal permeability in humans is much more difficult to obtain than in animal models. For example, probiotics cannot modify migraine-associated intestinal permeability changes\[[@B52]\] and a recent Finnish study demonstrated that nor probiotics nor long chain polyunsaturated fatty acid supplements can counteract intestinal permeability changes in pregnancy\[[@B53]\]. On the other hand, a potential improvement of intestinal permeability (assessed by an indirect test) induced by higher dietary fiber intake was observed after a longer dietary intervention\[[@B54]\]. We ask ourselves whether our result could be modified with a different duration of the observation and of the diet program.

A limitation of our study was the difficulty with recruitment because many patients refused to enrol for personal reasons. This limitation reflects the difficulty that patients experience adhering to a lifestyle intervention, which is far more compelling than taking medication. Larger longer-term studies are needed to confirm the durability of the benefits of a Mediterranean diet.

In conclusion, the Mediterranean diet is a safe and effective strategy for treating overweight, visceral obesity and serum transaminase in patients with NAFLD, thereby confirming that it should be the first step in a treatment program for patient with NAFLD. If the Mediterranean diet can improve intestinal permeability in patients with NAFLD, it deserves further investigation.
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Research background
-------------------

In patients with non-alcoholic fatty liver disease (NAFLD), intestinal permeability is increased, promoting translocation of bacteria-derived products into the portal circulation and increasing hepatic exposure to injurious substances that stimulate hepatic inflammation and fibrosis. In animal models, adaptation of a high-fat diet or high-fructose intake has been associated with increased gut permeability and metabolic endotoxiemia

Research motivation
-------------------

Although diet can significantly influence intestinal permeability, clinical studies investigating the effects of dietary interventions on the intestinal permeability of NAFLD patients are lacking. The Mediterranean diet contains a high intake of mono- and polyunsaturated fatty acids, fibres, polyphenols, antioxidants and phytochemicals; many of these components promote short-chain fatty acid-producing gut bacteria and have significant prebiotic effects. As such, we hypothesized a therapeutic effect of the Mediterranean diet for reducing impaired intestinal permeability in patients with NAFLD.

Research objectives
-------------------

Aim of the study is to detect diet-induced modification of intestinal permeability in patients with NAFLD undergoing a Mediterranean diet or a low-fat diet.

Research methods
----------------

Patients underwent a dietary treatment via a crossover design lasting 48 wk: 16-wk of a Mediterranean diet, 16-wk of a free wash-out diet and 16-wk of a low-fat diet. Intestinal permeability was evaluated at baseline and at the end of each diet period using the validated method of urinary excretion of chromium-51 ethylene diamine tetraacetate excretion testing (51Cr-EDTA). 51Cr-EDTA excretion is a good indicator of the severity of gut-mucosal inﬂammation and loss of tight junctions.

Research results
----------------

Patients with NAFLD experienced a significant reduction in body weight, waist circumference and transaminase levels after 16 wk of a Mediterranean diet. Seventy percent of patients had intestinal permeability alteration at baseline, but no significant changes in intestinal permeability were observed at the end of the Mediterranean diet period or at the end of the low-fat diet period.

Research conclusions
--------------------

The Mediterranean diet is a safe and effective strategy for treating overweight, visceral obesity and serum transaminase in patients with NAFLD, thereby confirming that it should be the first step in a treatment program. If the Mediterranean diet can improve intestinal permeability in patients with NAFLD, it deserves further investigation.

Research perspectives
---------------------

In our view, the modulation of intestinal permeability in humans is much more difficult to obtain than in animal models. We ask ourselves whether our result could be modified with a different duration of the observation and of the diet program.
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